GH
HealthcareGuardant Health, Inc.
$101.87
+$0.13 (+0.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Guardant Health, Inc. is a healthcare company operating in the diagnostics and research industry. With a market capitalization of $13.23 billion and annual revenues of $902.57 million, the company has established itself as a significant player in its sector. Guardant Health employs approximately 1999 individuals. The company's financial health indicates notable challenges. Its gross margin stands at 63.8%, while its operating margin is -37.3% and profit margin is -44.2%. The company reports negative net income of $398,788,992 and EBITDA of -$402,192,992 in the trailing twelve months. Furthermore, Guardant Health's return on assets (ROA) is -19.6%, indicating a loss for every dollar invested in assets. In terms of valuation context, Guardant Health has a forward P/E ratio of -69.85 and an EV/EBITDA ratio of -33.74. The company's price to sales ratio is 14.66, while its cash position stands at $580.01 million with debt amounting to $1.33 billion. Revenue growth over the past year has been significant, reaching 38.5%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Visit website →Key Statistics
- Market Cap
- $13.23B
- P/E Ratio
- N/A
- 52-Week High
- $112.43
- 52-Week Low
- $34.55
- Avg Volume
- 2.46M
- Beta
- 1.59
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NMS
- Country
- United States
- Employees
- 1,999